Publication Cover
Synthetic Communications
An International Journal for Rapid Communication of Synthetic Organic Chemistry
Volume 40, 2010 - Issue 3
124
Views
6
CrossRef citations to date
0
Altmetric
Original Articles

Synthesis and Evaluation of the Analogues for Galactosyl Donors as Inhibitors of β-1,4-Galactosyltransferase

, , &
Pages 328-336 | Received 28 Sep 2008, Published online: 06 Jan 2010
 

Abstract

The design and synthesis of analogs of galactosyl donors as potent and selective inhibitors of β-1,4-galactosyltransferase (β-1,4-GalT) are described. We employed a new strategy by incorporating 5-fluorouracil and an appropriate amino acid to galactose to prepare selective glycosyltransferase inhibitors. The in vitro cell assay showed that these compounds exhibited high cytotoxicity against the human leukemia cell line HL-60, human lung epithelial cell line A-549, and human liver cancer cell line BEL-7402, but low cytotoxicity against the murine leukemia cell line P388.

ACKNOWLEDGMENTS

We thank the Key International Cooperation Project of Ministry of Sciences and Technology, China (Grant No. 2008DFA31040) and National Basic Research Program (Grant No. 2003CB716403) for financial support. We also thank the National Center for Drug Screening in Shanghai Institute of Materia Medica, China, for biological testing.

Notes

a No inhibitory rate at 100 µM.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.